NCT04190654View on ClinicalTrials.gov

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions

Hepatic Impairment

Interventions

DRUG

KW-6356

Single oral dose of KW-6356

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

78229

Pinnacle Clinical Research, San Antonio

33014-3616

Clinical Pharmacology of Miami, LLC, Miami

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.

All Listed Sponsors

lead

Kyowa Kirin, Inc.

INDUSTRY